Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeneDx Holdings Corp. SEC filings page for ticker WGSWW provides access to the company’s U.S. regulatory disclosures, including current reports, annual and quarterly reports, proxy statements and documents describing its warrant securities. WGSWW represents warrants to purchase one share of GeneDx Holdings Corp. Class A common stock at a specified exercise price per share, and the detailed terms of these warrants are set out in registration statements and related filings.
Through these filings, GeneDx outlines its status as a Delaware corporation, its listing of warrants on The Nasdaq Stock Market LLC, and material corporate events such as changes in the size and composition of its Board of Directors. For example, a Form 8-K describes the appointment of a new Class I director, the increase in board size from seven to eight directors, the application of the Non-Employee Director Compensation Policy, and the company’s intention to enter into a standard form indemnity agreement with the director.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy reports, helping readers understand topics such as warrant terms, governance changes and references to compensation policies without reading every page. Real-time updates from the SEC’s EDGAR system ensure that new GeneDx filings appear promptly, while Form 4 and other insider-related reports can be reviewed to see how directors and officers interact with the company’s securities when such filings are made.
Users interested in GeneDx’s health insights and genomic focus can also use the filings to see how the company describes its activities, risk factors and data resources over time. The combination of original documents and AI-generated explanations makes it easier to interpret complex legal and financial language in the context of the WGSWW warrants and the underlying issuer.
GeneDx Holdings Corp. reported strong growth for 2025, with revenue rising to $427.5 million, up 41% year over year, and exome and genome test revenue reaching $360.3 million, up 54%. Adjusted gross margin improved to 71% and adjusted net income increased to $41.8 million from $9.4 million in 2024, while GAAP net loss narrowed to $21.0 million.
Fourth-quarter 2025 revenue was $121.0 million, including $104.0 million from exome and genome testing, with test volumes up 34.3% to 27,761. The company ended the year with $172.3 million in cash, cash equivalents, marketable securities and restricted cash and reaffirmed 2026 guidance for revenue of $540–$555 million, 33–35% exome and genome growth, adjusted gross margin of at least 70%, and positive adjusted net income.
GeneDx Holdings Corp. Chief Operating Officer Bryan Dechairo reported RSU vesting and related share sales. On February 1, 2026, 9,374 restricted stock units converted into an equal number of Class A Common shares at $0 per share upon vesting. On February 2, 2026, he sold a total of 3,413 shares in multiple transactions at weighted average prices between $96.7676 and $100.3146 per share to cover tax withholding obligations under a “sell to cover” arrangement, described as non-discretionary. Following these transactions, he directly beneficially owned 5,961 shares of Class A Common Stock and RSUs representing contingent rights to receive up to 28,123 additional shares, vesting over time subject to continued service.
A holder of WGS Class A common stock filed a notice of intent to sell 9,374 shares under Rule 144. The shares have an aggregate market value of 929900 and are part of 28,904,590 shares outstanding. The planned sale date is approximately 02/02/2026 on NASDAQ through Morgan Stanley Smith Barney.
The seller acquired the 9,374 shares of Class A common stock on 01/14/2025 as compensation in the form of restricted stock units from the issuer, with compensation as the nature of payment. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and related share sales. On January 29, 2026, 754 RSUs converted into the same number of Class A Common shares for no cash consideration.
On the same date, Feeley sold 315 shares at $94 and 2 shares at $92.0601. The company states these sales were made solely to cover tax withholding obligations through a “sell to cover” arrangement and were not discretionary trades. After these transactions, Feeley directly held 9,168 Class A Common shares, plus RSUs representing up to 112,750 shares and options for up to 25,906 shares, all vesting according to their existing schedules.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity activity tied to restricted stock units. On January 29, 2026 she settled 3,874 RSUs into the same number of Class A common shares for no cash cost, then sold 1,653 shares at a weighted average price of $93.9957 to cover tax withholding obligations through a non‑discretionary “sell to cover” transaction. After these moves she directly owned 16,458 Class A shares, along with RSUs representing contingent rights to receive up to 411,494 additional shares and options to purchase up to 107,610 shares, which vest according to their existing schedules.
A Form 144 notice shows a planned insider sale of 24,155 shares of Class A common stock, with an aggregate market value of $2,369,700. The shares are expected to be sold on or about 01/29/2026 on NASDAQ through Morgan Stanley Smith Barney.
The securities were acquired as compensation in the form of restricted stock units and performance-based restricted stock units on several dates between 2022 and 2025. The document also lists recent sales by Kevin Feeley over the past three months, including blocks such as 3,855 shares on 12/16/2025 for gross proceeds of $554,632.
WGS insider Katherine Stueland has filed a notice of proposed sale of 94,495 shares of Class A common stock through broker Morgan Stanley Smith Barney on NASDAQ. The filing lists an aggregate market value of 9268700 for these shares and shows 28,904,590 shares of this class outstanding.
The shares to be sold were acquired as equity compensation, including restricted stock units and performance-based restricted stock units granted between 2022 and 2025. The notice also reports prior sales over the last three months, including 2,158, 3,639, and 10,857 shares of Class A common stock, with stated gross proceeds for each transaction.
Thomas Fuchs, a director of GeneDx Holdings Corp. (ticker shown as WGS), was granted 3,438 restricted stock units (RSUs) on 09/17/2025. Each RSU converts into one share of Class A Common Stock for no consideration when settled. The award vests in three equal installments on 09/17/2026, 09/17/2027, and 09/17/2028, subject to the reporting persons continued service. Following the grant, the reporting person beneficially owns 3,438 shares of Class A Common Stock as a direct owner. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
Thomas Fuchs filed an initial Form 3 reporting his relationship to GeneDx Holdings Corp. (ticker: WGS) as a Director. The event date triggering the filing is 09/17/2025. The form states that no securities are beneficially owned by the reporting person. The filing is signed on behalf of Mr. Fuchs by Bridget Brown, Attorney-in-Fact dated 09/19/2025.
Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. amended a Form 4 to correct a typographical error and to report the vesting and acquisition of restricted stock units. The amendment clarifies that on 09/16/2025 Mr. Feeley acquired 7,197 restricted stock units, each convertible into one share of Class A common stock for no consideration, increasing his beneficial ownership to 12,483 shares.
The filing notes the original Form 4 filed on 09/18/2025 incorrectly showed a disposition code where an acquisition code was intended; no other line items were changed. The amendment is signed by an attorney-in-fact on behalf of the reporting person.